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Background: Locally advanced head and neck cancer is managed either by
combined surgery and (chemo) radiotherapy or definitive (chemo) radiotherapy,
which may deteriorate nutritional status. Previous data have shown that intensive
nutritional intervention by a dietician reduces radiation-induced adverse events including
weight loss.
Objective: To determine if on-demand nutritional counseling (ODC, control group) would
be as efficacious as intensive nutritional counseling (INC, experimental group) in patients
undergoing (chemo) radiotherapy.
Methods: Fifty-eight patients were randomly assigned to receive INC (n = 26) or ODC
(n = 32). Outcome measures were nutritional status (PG-SGA), weight loss, handgrip
strength (HGS), body composition, and survival.
Results: Weight loss and impaired nutritional parameters during oncological treatment
were seen equally in both groups (NS). Leaner patients at baseline maintained their
weight, while overweight patients lost both weight and handgrip strength during
treatment. Disease-free survival (DFS) (median = 43 months) was not affected by weight
loss during treatment. Lower baseline HGS and malnutrition were associated with worse
DFS (low vs. normal HGS: 15 vs. 42 months; p= 0.05 and malnutrition vs. good nutrition
status: 17 vs. 42 months; p = 0.014, respectively). Survival according to low vs. normal
HGS in the INC group was 4 vs. 44 months (p = 0.007) and in the ODC group 28
vs. 40 months (p = 0.944). According to malnutrition vs. good nutritional status in the
INC group, DFS was 21 vs. 43 months (p = 0.025) and in the ODC group 15 vs. 41
months (p = 0.03).
Conclusions: As for our primary endpoint, individualized on-demand nutritional
counseling was as efficacious as intensive counseling in preventing deterioration
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of nutritional status and incidence of malnutrition during (chemo) radiotherapy. This
should be verified with larger number of patients. Additional findings were that overweight
patients had more severe weight loss, but not poorer survival. Low HGS and malnutrition
at baseline were associated with poor survival.
Clinical Trial Registration: www.ClinicalTrials.gov, identifier NCT02159508.
Keywords: nutritional status, handgrip strength, nutritional intervention, survival, weight loss
INTRODUCTION
Adjuvant chemo (radiotherapy) for locally advanced head and
neck squamous cell cancer (HNSCC) results in better survival
than radiotherapy alone but causes worse oral and systemic
symptoms and decreased food intake and thereby causes weight
loss and adverse outcomes (1). Nutritional treatment has an
essential role in the management of HNSCC to prevent both
disease and treatment-related weight loss (2). In addition,
malnutrition prior to diagnosis and during treatment predicts
poorer survival in HNSCC (3, 4).
Weight loss is a major predictive marker for impaired
response to cancer treatment and poor survival (3, 5, 6).
Most patients with locally advanced HNSCC report weight
loss already before diagnosis, which tends to persist during
anti-neoplastic treatments, mainly due to acute adverse effects
of chemoradiotherapy (6). The reported incidence of critical
weight is around 17–28% before treatment and 50–80% at the
end of treatment, depending on the tumor location, stage, and
treatment modality (7–11). A recent study on nasopharyngeal
cancer showed that 20% of patients lost more than 10% of
weight during chemoradiotherapy (12). There are a few studies
in patients with head and neck cancer referred to adjuvant anti-
neoplastic treatments demonstrating that early nutritional
intervention stabilizes nutritional status and improves
nutritional intake (2, 5, 13–15), furthermore the American
Dietetic Association Medical Nutrition Therapy Protocol
has been found to be effective in physiological and clinically
relevant outcomes in head and neck cancer patients undergoing
radiotherapy (2, 13, 14, 16).
In head and neck cancer, benefits on nutritional status,
nutritional intake, functional status, symptoms, and quality of
life have been demonstrated when individualized counseling is
performed vs. no counseling or vs. general nutrition advice given
by a nurse (5, 17–19).More importantly, a randomized controlled
trial in colorectal cancer patients showed improved survival in
patients who received individualized nutritional counseling when
compared with the group that received standard of care (20).
The potential difference in the effect of individualized
intensive nutritional counseling given by a dietician vs. on-
demand individualized counseling has not been previously
explored. This is a topical issue due to the need to provide
dietetic services more efficiently and with limited resources
as expected. The primary endpoint measure of this study
was the efficacy of nutritional intervention on nutritional
status. We established as secondary endpoints the efficacy of
intensive nutritional counseling on body composition, handgrip
strength, treatment-related adverse events, and survival. The
results will be useful for the development of a nutritional
treatment protocol at our Department, potentially adaptable by
other departments.
MATERIALS AND METHODS
Trial Design
This open labeled, parallel-group, exploratory randomized trial
was conducted at the Helsinki University Hospital, Helsinki,
Finland. The study design followed the guidelines laid down
in the Declaration of Helsinki and all procedures involving
human patients were approved by the institutional Research
Ethics Committee. Written informed consent was obtained from
all patients.
Patients
Inclusion criteria were: patients with locally advanced (Stage III-
IV) squamous cell carcinoma of the oral cavity, oropharynx,
hypopharynx, nasopharynx, or larynx, referred for a curative
treatment with combined surgery and adjuvant (chemo)
radiotherapy, or definitive (chemo) radiotherapy, who were
18–80 years old and gave their written informed consent.
Exclusion criteria included: renal function impairment (serum
creatinine >1.5 times upper limit of normal [ULN]), liver failure
(serum bilirubin >1.5 times ULN), heart failure, cor pulmonale,
COPD or cognitive impairment. Patients were also excluded
if they had had a previous cancer in any location, or if they
were recommended for palliative treatment with no curative
therapeutic options.
This study was conducted between November 2007 and
December 2009. Eligible patients according to the inclusion
criteria were randomly assigned to one of the two study
groups: intensive nutritional counseling (INC, experimental
group) or on-demand counseling (ODC, control group); the
groups differed in the number of nutrition consultations during
treatment; INC consisted of protocol counseling given by a
dietician at baseline, on the 2nd and 4th week of treatment,
and at the end of chemoradiotherapy. In the ODC group
patients received baseline nutritional counseling, that consisted
of one dietetic consultation before chemoradiotherapy. During
chemoradiotherapy ODC patients received counseling only on
demand. In the ODC group, the criteria for physicians to
request for nutritional intervention were any concerns regarding
intake (typically weight loss >5%, or any symptoms referring
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to significant decrease in nutritional intake). There were three
staff physicians involved in this trial who were fully aware of the
criteria for referring patients for a dietician consultation.
Randomization was performed by the minimization
procedure (21) with the Minim Program R© (http://www-
users.york.ac.uk~mb55/guide/randsery.htm). The allocation was
done according to the following criteria: (1) Stage I-II vs. Stage
III-IV; (2) age<65 vs.≥65 year; (3) Body Mass Index (BMI)<20
vs. ≥20 kg/m2, and (4) tumor location (oral cavity-oropharynx-
tonsils vs. hypopharynx-larynx vs. nasopharynx). The allocation
ratio was 1:1. Randomization into the INC and ODC groups
was performed after the cancer diagnosis had been established
and oncological treatment approach for each patient had been
discussed at the multidisciplinary tumor board meeting.
Management decisions were based on the Finnish national
guidelines for the treatment of HNSCC and were dependent on
the tumor location and stage and on patient’s general health
status. Patients were recruited at their first outpatient visit at the
Department of Otorhinolaryngology—Head andNeck Surgery of
Helsinki University Hospital after the Multidisciplinary Tumor
Board Meeting.
Surgery and Oncologic Treatment
Tumor resection in the oral cavity and/or oropharynx was
typically accompanied with a free-tissue reconstruction and
with unilateral or bilateral modified radical neck dissection.
Reconstruction after a total laryngectomy was performed
by primary closure, with myocutaneous flap reconstruction,
or with free tissue transfer. Adjuvant therapy after surgery
consisted of concurrent radiotherapy or chemoradiotherapy
using computed tomography-planned intensity-modulated
radiotherapy with photons from amegavoltage linear accelerator.
Hypopharyngeal and certain laryngeal and oropharyngeal
tumors were treated with definitive chemoradiotherapy.
Radiotherapy was given once a day and all patients received
standard 60–70Gy in 30–35 fractions over a period of 6–7
weeks. Treatment fields included the primary tumor site and
neck. All patients received standard cisplatin-based regimens as
adjuvant radiosensitisers.
Adverse events of chemoradiotherapy were classified
according to the National Cancer Institute Common
Terminology Criteria for Adverse Events-3.0 (CTCAEv3.0)
(22). Assessment was performed before initiation of
chemoradiotherapy, at the second week and at the end of
treatment. Objective grading was performed by a radiation
oncologist (KS) or by a dietician (HO) and Grade 3 adverse
events were classified as severe adverse events.
Nutritional Intervention
At our institution prophylactic PEG is inserted to almost all
HNSCC patients either prior to surgery or before the start of
chemoradiotherapy. Tube feeding was planned and instructed
(i.e., enteral formula, volume [ml/day]) for all 51 patients with
PEG according to personalized energy and protein requirements.
Nutritional requirements were calculated according to WHO
formula multiplied by activity factor 1.5 (23) and protein 1.3–
1.5 g/kg/day (BMI 22). In this study, PEG was inserted for 88%
of patients. Three patients referred for chemoradiotherapy did
not consent to PEG placement, while 4 patients were considered
not to need PEG. Nutritional counseling in both study groups
was individualized given by a dietician, aiming to achieve and
maintain patient’s calculated energy and protein intake during
(chemo) radiotherapy, either by PEG or via oral route.
Enteral formulas containing either 1 kcal/ml (0.3 g/ml protein,
Nutrison R© Multi Fiber, Nutricia, N.V. Nutricia, Zoetermeer,
Holland) or 1.5 kcal/ml energy (0.6 g/ml protein, Nutrison R©
Energy Multi Fiber) were used. The INC group patients started
tube feeding according to dietitian’s instructions during RT. The
ODC group patients were instructed to start tube feeding when
their dietary intake was <60% of the usual intake or at the latest
on the third week of RT.
All patients received protocoled nutritional counseling, which
included dietary prescription (i.e., tube feeding, product, and
volume) and counseling for energy- and protein-dense texture-
modified diet via a dietary booklet. The latter booklet included
meal plans and recipes for energy- and protein-dense texture
modified meals for oral intake designed for the current study
(15 pages). During chemoradiotherapy the INC group included
a protocol assessment of nutritional intake and fine-tuning
nutrition plan or nutrition for tube feeding according to
treatment side-effects. ODC was done when requested by the
attending physician.
Nutritional Status
Patient characteristics included: age, sex, body weight (kg), height
(cm), and recalled body weight at 1 and 6 months, previous
to surgery, to definitive chemoradiotherapy or radiotherapy
alone; hereafter named as chemoradiotherapy (baseline). Body
weight, handgrip strength, and the full version of the PG-
SGA© (Data Sheet 1) were evaluated at baseline and at the sixth
or seventh week of chemoradiotherapy (end). Dietary intake
related problems were evaluated by PG-SGA© (24). Patients were
classified as well-nourished (PG-SGA A) or malnourished (PG-
SGA BC), and a total PG-SGA score was calculated as described
by Ottery (24, 25). Permission for the full form of scored PG-
SGA© was received from Pt-Global (http://pt-global.org/).
Weight and Body Composition
All patients were weighed using the same calibrated scale (Tanita,
Illinois, USA R©). The criterion for pre-treatment critical weight
loss was either ≥5% in 1 month or ≥10% in the previous 6
months (11, 26–28). Critical weight loss during treatment was
defined as >5% unintentional weight loss of baseline weight
(29) and it was categorized into 2 groups: ≤5, >5%. BMI was
classified as underweight if <20 kg/m2, normal 20–25 kg/m2, or
overweight if >25 kg/m2 (30).
Body composition was assessed by bioimpedance using a
single frequency (50 kHz) two-terminal bio-impedance meter
(Bodystat Ltd, Isle of Man, UK R©) performed according to
standard procedure (31), by the same dietician (HO). Patients
were in supine position with no body parts touching the torso.
Electrodes were placed on the patient’s right hand and foot using
a four-surface standard electrode technique.
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Total body water was calculated by the Kotler equations
(32). The theoretical normal hydration of fat-free tissue was
assumed and calculated as 0.73. Fat mass (FM) was calculated
as the difference between body mass and fat-free mass (FFM).
Percentage of FM was calculated by dividing total weight
of FM (kg) by total body weight (kg) and FFM percentage
subtracting FM percentage from 100. Fat-free mass index (FFMI)
was calculated by dividing FFM (kg) by the square of the
body height (m2).
Muscle Mass Function
Skeletal muscle function was assessed bymeasuringHGS for both
arms with a JAMAR R© dynamometer (Sammons Preston Rolyan,
Chicago, USA R©). Patients performed the test while sitting
comfortably with adducted shoulders and forearm neutrally
rotated, elbow flexed to 90◦, and forearm and wrist in neutral
position. According to the manufacturer’s instructions, the
instrument was adjusted for hand size; position “3” was used
for men, and position “2” for women. Patients were instructed
to perform a maximal isometric contraction. The test was
repeated within 30 s and the mean of three measurements for the
dominant hand was used for the analysis (33, 34). Values were
compared with age and sex appropriate reference values. A cut-
off point below the 5th percentile was used as an indicator of
muscle mass dysfunction (34).
Survival
Overall survival (OS) was defined as the time interval between
the date of the randomization and the date of the last visit or
death by any cause. Disease-specific survival (DSS) was defined
as percentage of patients who had not died from HNSCC during
that time period. The assessment period was from the time of
diagnosis to the date of last visit or HNSCC-related death. Death
from other cause than HNSCC was not defined as an event
for DSS. Disease-free survival (DFS) was calculated from the
completion of treatment to the detection of cancer recurrence
or death of any cause according to the National Cancer Institute
(http://www.cancer.gov/dictionary?cdrid=44023). The follow-up
of HNSCC patients at our institution is scheduled according
to the national protocol and therefore, there was no difference
between the study groups regarding this issue.
Sample Size Calculation
We performed power analysis before the beginning of the study.
A sample size of 102 patients was identified to achieve 30%
reduction in prevalence of malnutrition at the end of treatment
(50–20%), with a significance value of 5% (p < 0.05) and
90% power. The required number of patients decreased to 88
when we updated the calculation later and decreased the power
requirement from 90 to 85%. Based on the updated calculations,
our aimwas to recruit 100 patients, with the assumption that 12%
of patients would be lost to follow-up.
However, during 18 months of recruitment we managed to
recruit only 65 patients due to many recruitment problems and
it was clear that the number of 100 patients was unrealistic to
be achieved. With the sample size of 65 patients (26 in INC and
32 in ODC), the estimated power was only 60% to show the
difference (50–20%) statistically significant. Although an interim
analysis was not preplanned in the study protocol, the check
of apparent treatment difference with respect to the primary
outcome measure, nutritional status, was needed. In the interim
analysis of 58 patients, 32 patients in the INC group, and 26
patients in the ODC group, the baseline-adjusted odds ratio for
malnutrition was 1.70 (95% CI 0.43–6.79, p = 0.45) when ODC
was compared to INC. Although the treatment difference was
not statistically significant, the study was discontinued due to
appearance of a negative trend, where the direction was opposite
to the one expected and because the 95% confidence interval did
not include the predefined relative risk reduction of 60%. With a
half-sample-size, INC superior to ODC (even if not significant)
makes it very unlikely to obtain a significant opposite result with
the planned sample size. The conditional power i.e., probability
of obtaining a significant relative risk reduction considering the
intermediate results is <58%.
Statistical Analysis
For statistical data analyses, we included patients who fulfilled
the treatment plan with follow-up appointments and assessments
and did not perform an intention-to-treat analysis. All statistical
analyses were performed with SPSS Statistical software (Version
19.0, IBM Corp., Armonk, NY, USA R©).
Logistic regression analysis was used in the interim analysis
when the presence of malnutrition (based on PG-SGA) in ODC
was compared to INC. The baseline nutrition status was included
as a categorical covariate. The result is given as odds ratio (OR)
with 95% confidence interval.Weight, BMI, FFM, FFMI, FM, and
HGS were normally distributed for both INC and ODC groups,
as assessed by Shapiro-Wilk’s test (p > 0.05). The homogeneity
of regression slopes was attained and standardized residuals
for the interventions were normally distributed, as assessed by
Shapiro-Wilk’s test (p > 0.05). There was homoscedasticity,
as assessed by visual inspection of the standardized residuals
plotted against the predicted values. There was homogeneity
of variances, as assessed by Levene’s test of homogeneity of
variance. There were no outliers in the data, as assessed by no
cases with standardized residuals > ±3 standard deviations.
Descriptive data were expressed as median (interquartile ranges,
IQ range).
Between-group comparisons were analyzed with one-way
ANCOVA or two-way ANCOVA when appropriate. Between-
group comparisons were analyzed with non-parametric Mann-
Whitney’s U-test or Kruskal-Wallis tests, as appropriate. All
patients were kept in the group (INC n = 26, ODC n = 32)
where they were assigned by the randomization system. Repeated
measures were analyzed by Sign test or Wilcoxon signed-ranks
test, and categorical variables by related samples McNemar
test; category variables. Prevalence or frequency were evaluated
by the X2 test. Correlations were analyzed by non-parametric
Spearman rho and Kendal’s tau. Prevalence and frequency were
expressed as number and percentage. The Kaplan–Meier method
was used to calculate survival and the log-rank test statistic was
used to evaluate the equality of survival distributions across
different strata. A two-tailed p-value below 0.05 was considered
statistically significant.
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FIGURE 1 | Study flowchart.
RESULTS
Patients
Altogether, 88 patients were eligible for inclusion and 65 (74%)
gave their written informed consent to participate in the study.
There were 23 patients who were not included in the study, 7
patients denied participation, 2 participated in another clinical
trial, and 14 were lost due to logistic reasons (Figure 1). Of the
65 participants, 32 were randomly assigned to receive intensive
individualized counseling (INC) and 33 to receive individualized
on-demand counseling (ODC). Fifty-eight patients completed
the treatment assessment, 1 patient withdrew his consent, 3 died
and 3 discontinued their treatment due to disease progression.
Most patients were male (79%), 22% were >65 years old, and
the median age (range) for the 58 study patients, was 61 years
old (33–73) for men and 59 years old (42–73) for women. The
minimum follow-up time for both groups (INC and ODC) was
40 months or until death.
With the recruitment of the 65 patients, we maintained a
significance value of 5% (p < 0.05) with 60% power. At this
time point, and with 58 patients recruited for 2 years, we had to
perform an unplanned pre-analysis due to recruitment problems.
In the interim analysis of 58 patients, 32 patients in the control
group (ODC) and 26 patients in the treatment group (INC), the
baseline-adjusted odds ratio for malnutrition (PG-SGA BC) was
1.70 (95% CI 0.43–6.79, p= 0.45).
Baseline characteristics of the two study groups (INC and
ODC) are presented in Tables 1, 2. The two groups were
comparable and homogeneous at baseline in terms of age,
sex, tumor location and stage. In the ODC group there were
significantly more patients with T4 tumor stage (p = 0.02), and
PEG dependence (p= 0.002), yet groups were balanced for PEG;
the ODC group more often received chemoradiotherapy (p =
0.03) vs. patients in the INC group. Likewise, baseline variables
did not differ between groups. TheODC group hadmore patients
with malnutrition (p = 0.03), prophylactic PEG (p = 0.001),
and chemoradiotherapy (p = 0.03) compared with those in the
INC group.
Although the treatment difference was not statistically
significant, the study was discontinued due to apparent negative
trend, where the direction was opposite to the one expected
and because the 95% confidence interval did not include
the predefined relative risk reduction of 60%. With a half-
sample-size as the one calculated and a control superior to
active treatment (even if not significant) makes it unlikely to
obtain a significant opposite result with the planned sample
size. The conditional power i.e., probability of obtaining a
significant relative risk reduction considering the intermediate
results is <58%.
Nutritional Outcomes
At the end of treatment, overall parameters were worse and there
were no significant differences between study groups (Table 2).
In detail concerning the primary endpoint, the prevalence of
malnutrition according to PG-SGA increased during treatment
from 27 to 85% in the INC group (p < 0.001) and from 44 to
75% in the ODC group (p= 0.007). Median PG-SGA score for all
patients increased significantly during treatment (p < 0.001). At
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TABLE 1 | Baseline characteristics of the two study groups.
Baseline characteristics INC ODC p-valuea
Number of patients (%) 26 (45) 32 (55)
Age y, median (IQ range) 57 (52–64) 61 (56–64) 0.320
≥65 y, n (%) 6 (23) 7 (22) 0.365
Males, n (%) 21 (81) 25 (78) 0.412
BMI, kg/m2, n (%)
<20 3 (12) 6 (19) 0.095
20–25 9 (35) 15 (47) 0.089
>25 14 (54) 11 (34) 0.869
Malnourished (PG-SGA BC), n (%) 7 (27) 14 (44) 0.039
PEG, n (%) 20 (78) 31 (97) 0.002
Tumor location, n (%)
Oral cavity 3 (12) 3 (9) 0.363
Oropharynx 11 (43) 13 (41) 0.399
Hypopharynx 4 (15) 5 (16) 0.292
Larynx 5 (19) 7 (22) 0.236
Nasopharynx 2 (8) 4 (12) 0.106
Unknown 1 (4) –
Stage, n (%)
I 1 (4) 1(3) 0.190
II 2 (8) 4 (12) 0.106
III 6 (23) 6 (19) 0.475
IV 16 (62) 21 (66) 0.237
Unknown 1 (4) –
Stage III–IV, n (%) 22 (85) 27 (84) 0.309
T Class, n (%)
T1 7 (27) 4 (12) 0.816
T2 7 (27) 8 (25) 0.395
T3 6 (23) 8 (25) 0.269
T4 5 (19) 12 (38) 0.022
Unknown 1 (4) –
N Class, n (%)
N0 9 (35) 11(34) 0.352
N1 3 (12) 3 (9) 0.363
N2 13 (50) 18 (56) 0.196
N3 1 (4) –
Treatment plan, n (%)
Surgery + chemoradiotherapy 6 (23) 5 (16) 0.593
Surgery + radiotherapy 1 (4) 1 (3) 0.190
Chemoradiotherapy 16 (61) 25 (78) 0.036
Radiotherapy 3 (12) 1 (3) 0.688
Smoking, pack years, n (%) 17.5 (1–36) 37.6 (12–54) 0.013
Alcohol, drinks per week, n (%) 2.5 (1–9) 9 (1–21) 0.088
IQ interquartile, BMI body mass index, PG-SGA, patient generated subjective global
assessment; T, tumor; N, node; PEG, percutaneous gastrostomy; INC, intensive
nutrition counseling; ODC, on-demand nutritional counseling. Data expressed as median
(interquartile range) or number (%).
ap-value Mann-Whitney or X2 test between INC and ODC group.
baseline, 22% (n= 13/58) of patients needed critical intervention
(≥9 points), and at the end of treatment this proportion of
patients increased to 71% (n = 41/58). There was no difference
in body composition and function between the two study groups
neither at baseline nor at the end of treatment (Table 2).
Weight Loss
At baseline, critical weight loss was seen in 24% (n = 14/58)
of all patients. Ten out of these 14 patients had this weight
loss during the previous month (median 6.1%, IQ range 5–10)
and 11 patients reported critical weight loss in the previous 6
months (12.1%, 12–14). Fifty percent (n = 7/14) had critical
weight loss both during the previous month and in the past
6-month period. Critical pre-treatment weight loss was similar
in the two study groups: 23% (n = 6/26) in the INC and 25%
(n = 8/32) in the ODC (p = 0.269). In a similar fashion, at
the end of chemoradiotherapy, 71% (n = 41/58) of all patients
had lost >5% of weight with a median weight loss of 7.7% (IQ
range 7–11). Critical weight loss was similar in both groups:
77% (n = 20/26) in the INC group (median 8.4%, IQ range 7–
11) and 67% (n = 21/32) in the ODC group (median 7.1%, IQ
range 7–10, p= 0.704).
An additional finding was that prevalence of overweight
patients decreased from 43 to 26% (p = 0.921), and
underweight patients increased from 16 to 28% (p =
0.012). Forty-one percent of patients in the INC group
and 47% in the ODC group remained within normal
weight range, and there were no significant differences
between groups.
Nutritional Intake
At the end of treatment, overall median (IQ range) for energy
intake was 82% (68–91) of estimated requirements and median
protein intake was 72% (60–81) of estimated requirements; we
did not find significant differences between the two study groups.
In detail, median energy intake was 27.5 kcal/kg in the INC group
(2,000 kcal/day) and 29.5 kcal/kg (1,950 kcal/day) in the ODC
group (p= 0.24, NS). Regarding energy intake, 26% of all patients
reached>90% of estimated energy needs, 19% (n= 5/26) of them
in the INC and 31% (n = 10/32) in the ODC group (INC vs.
ODC, p= 0.06). Furthermore, 12% of all patients reached >90%
of estimated protein needs: three patients in INC and four in the
ODC group, p= 0.243).
Six (10%) of all patients were PEG dependent prior to
diagnosis, while 45 patients started to use PEG on median (IQ
range) of 16th (11–22) day from the start of chemoradiotherapy.
The median (IQ range) PEG dependency was 4 (2–9) months.
One patient in the ODC group denied using PEG. There was no
difference in the follow-up regarding PEG dependence and usage
as a nutritional route.
Handgrip Strength
At baseline, median (IQ range) HGS in females was 22 kg
(20–31) and 39 kg (31–49) for men; at the end of treatment,
results were 22 kg (18–29) and 35 kg (28–46), respectively.
There were no significant differences between INC and ODC
groups. At baseline malnourished patients (PG-SGA BC) had
significantly lower HGS (p= 0.001) than well-nourished patients
(PG-SGA A) and it decreased during treatment in both sub-
groups. Median (IQ range) HGS in malnourished patients was
at baseline 28 kg (22–38) and at the end of treatment 27 kg
(20–31) (p = 0.24), in well-nourished patients 39 kg (33–49)
and 38 kg (29–47) (p = 0.001), respectively. Low HGS at
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TABLE 2 | Nutritional characteristics at baseline and end of treatment for all 58 patients and for two study groups.
INC
(n = 26)
ODC
(n = 32)
Baseline adjusted mean difference
at the end of treatment, Mean (95% CI)a
Characteristics Baseline End Baseline End INC ODC P-value
Weight, kg 79.2 (63–87) 71.4 (58–81) 69.7 (57–82) 65.8 (55–78) 68.3 (67.0, 69.6) 68.7 (67.5, 69.8) 0.690
BMI, kg/m2 24.8 (22–28) 23.3 (20–26) 23.1 (21–26) 22.4 (19–24) 22.7 (22.2, 23.1) 22.8 (22.4, 23.1) 0.656
FFMI, kg/m2 19.4 (18–22) 18.8 (16–20) 18.8 (27–20) 17.4 (16–20) 18.3 (17.8, 18.7) 18.4 (18.0, 18.7) 0.741
FFM, kg 62.0 (48–69) 57.0 (47–64) 58.8 (48–62) 54.0 (46–62) 55.1 (53.8, 56.4) 55.4 (54.2, 56.6) 0.684
FM, kg 16.9 (10–21) 14.0 (10–17) 14.0 (10–20) 11.1 (10–16) 13.4 (12.6, 14.2) 12.8 (12.1, 13.6) 0.332
HGS, kg 37.4 (31–49) 30.7 (26–46) 36.4 (26–43) 31.4 (23–40) 33.8 (32.1. 35.5) 33.5 (31.9, 35.1) 0.803
Data presented as median, IQ (interquartile) range. INC, intensive nutritional counseling; ODC, on-demand counseling; CI, confidence interval; BMI, body mass index; FFMI, fat-free
mass index; FFM, fat-free mass; FM, fat mass; HGS, handgrip strength; aBaseline-adjusted mean difference (95% CI) at the end of treatment, where the baseline measurement is
included as a continuous covariate (ANCOVA). INC group patients are compared to ODC group patients.
FIGURE 2 | (A) Kaplan-Meier survival plot: overall survival by baseline
handgrip strength. (B) Kaplan-Meier survival plot: disease-free survival by
baseline handgrip strength.
baseline (<5th percentile reference values) was seen in 17%
(n= 10/58) and at the end of treatment in 31% (n= 18/58) of all
patients (p= 0.008).
Treatment-Related Adverse Events
Sixty-one per cent (n = 14/23) of patients in the INC group
completed their prescribed chemotherapy and 60% (n = 18/30)
in the ODC group (p = 0.326); 92% (n = 24/26); and 91% (n =
29/32) completed their scheduled radiotherapy, respectively (p=
0.380). In both groups, five patients were admitted to the hospital
during chemoradiotherapy and one patient had to discontinue
radiotherapy for>5 days in the INC group. Severe mucositis was
seen in 19% (n = 5/26) of patients in the INC group and in 25%
(8/32) of patients in the ODC group (p= 0.161).
Of the patients who had lost ≤10% of weight during
treatment, 48% (n = 21/44) completed the planned
chemotherapy, 89% (n = 39/44) completed their scheduled
radiotherapy, and 23% (n = 10/44) had hospital admissions. In
contrast, for patients with >10% weight loss these figures were
86% (n= 12/14) and 100% (n= 14/14), respectively (p < 0.001),
and they had no hospital admissions. Severe mucositis was seen
in 25% (n = 11/44) patients with ≤10% weight loss vs. 14% (n
= 2/14) of patients with weight loss >10% (p = 692). Severe
nausea was seen significantly more in patients with >10% weight
loss as compared with patients with ≤10% weight loss, 29% (n=
4/14) vs. 5% (n= 2/44), p= 0.01. A linear correlation was found
between percentage weight during treatment and the severity of
anorexia in all patients (r = −0.34; p < 0.01) explaining the 11%
variation in weight loss.
Majority of all patients (69%, n = 40/58) were not able
to carry out their planned nutritional treatment. The main
patient-reported problems for unsuccessful nutritional intake
were nausea (22%, n = 13/58), early satiety (12%, n = 7/58), loss
of motivation (9%, n = 5/58), or miscellaneous reasons (21%,
n= 12/58, e.g. PEG related causes, exhaustion, cachexia, financial
issues and severe diarrhea).
Survival
Median follow-up for all study participants was 43months (range
6–63); 46 months in the INC group and 42 months in the
ODC group (p = 0.189). The 5-year OS for all patients was 60;
69% (18/26) in the INC group and 53% (17/32) in the ODC
group (p = 0.81). DSS rates were 75% (18/24) and 68% (17/25),
respectively (p = 562), and DFS rates 65% (17/26) and 41%
(13/32), respectively (p= 939). DSS and DFS for all patients were
71 and 52%, respectively.
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The 5-year OS for patients with baseline low HGS was
20% (2/10) and for normal HGS 69% (33/48, p = 0.004). The
DFS rates were 20% (2/10) and 58% (28/48), respectively (p
= 0.03). Kaplan-Meier survival analysis showed that patients
with low HGS (<5th percentile) at baseline had significantly
poorer median OS (Figure 2A) and shorter DFS (Figure 2B)
than patients with normal HGS. The 5-year OS for patients with
baseline malnutrition (PG-SGA BC) was 43% (9/21) and for
well-nourished 70% (26/37, p = 0.04). The median OS was 38
months (95% CI 28–47 months) for malnourished patients and
50 months (95% CI 43–56 months) for well-nourished patients
(Log-rank test p= 0.035).
HNSCC was the primary cause of death in 22% (n= 13/58) of
all patients; local recurrence was seen in 12 patients and distant
metastases in one patient in INC group. In the INC group six
patients died due to HNSCC and one due to pneumonia. In the
ODC group seven died due to HNSCC and the other causes of
death were secondary cancers (n = 2), ileus, pneumonia (n = 2),
and unknown cause of death (n= 2).
Efficacy of Nutritional Intervention
Proportional ratios of patients that maintained good nutritional
status (PG-SGA A), good FFM (FFM loss <5%), normal HGS
(>5th percentile) and stable weight (weight loss ≤5%) in the
INC and ODC groups were calculated to analyse the efficiency
of nutritional intervention. In the INC group, 15% maintained a
good nutritional status, 23% their body weight, 54% of patients
maintained their muscle mass, and 77% their HGS, whilst in
the ODC group, the respective proportions were 22, 32, 53,
66% (NS).
Nutritional characteristics according to baseline nutritional
status and BMI are shown in Table 3. There was a trend for
higher pre-treatment BMI (≥25) to be associated with more
severe weight loss compared with normal weight patients (BMI
<25): median (IQ range) weight loss of 3.2 (1–5) kg vs. 7.1
(5–9) kg (p < 0.001), respectively. After adjustment for pre-
intervention weight loss, there was a statistically significant
difference in treatment induced weight loss between two BMI
groups, F(1, 51) = 5.609, p = 0.021, partial η
2 = 0.093 and
baseline nutritional status groups, F(1, 55) = 5.580, p = 0.022,
partial η2 = 0.093 (Table 3). Post-hoc analysis was performed
with a Bonferroni adjustment. Treatment-induced weight loss
was statistically significantly greater in the group with baseline
overweight (BMI ≥ 25 kg/m2) vs. the group with normal weight
(BMI < 25 kg/m2) with the mean difference of 2.8 (95% CI,
1.127–4.373) kg, p < 0.001. Despite weight loss, malnourished
patients did not lose FFM during treatment (p = 0.033). At the
end of treatment overweight patients and well-nourished patients
still had significantly higher FFM (p = 0.005 and p < 0.001,
respectively) and HGS (p = 0.001 and p < 0.001, respectively)
despite weight loss. Malnourished patients had higher median
(IQ range) energy intake 31 (28–32) kcal/kg) at the end of
treatment as compared with the well-nourished patients [26 (21–
20) kcal/kg, p = 0.010]. The same trend was seen also between
those with normal weight and overweight patients at baseline; 31
(28–34) kcal/kg, and 25 (21–28) kcal/kg, respectively (p < 0.001).
There was no statistically significant correlation between type
of nutritional counseling (INC vs. ODC) and baseline nutritional
status (according to PG-SGA) for weight, weight loss, FFM,
FFMI, FM, and HGS analyzed by two-way ANCOVA (Data
not shown).
DISCUSSION
The aim of the study was to evaluate the effect of nutritional
intervention on HNSCC patients’ nutritional status in a
prospective randomized trial setting with two modalities. Aware
of the limitations of this study inherent from the reduced number
of patients in each study arm, we can only provide exploratory
data. However, by paired analyses between the studied groups,
we detected a trend for intensive nutrition counseling and on-
demand counseling to stabilize nutrition status equally in patients
with pre-treatment weight loss. Furthermore, these were not
able to prevent FFM loss in these populations except in baseline
malnourished patients.
There were no differences in the two nutritional counseling
methods on nutritional status, or in any of the secondary
endpoints (FFM, HGS, survival). Pre-treatment low HGS and
malnutrition by PG-SGA were associated with poorer survival
whereas treatment induced weight loss or malnutrition did not.
This might be due to the research protocol used in this study.
We did not compare results with a control group without any
nutrition; instead we compared two modalities of nutritional
intervention during treatment. This study also showed that
physicians and nurses paid attention to nutritional problems and
used dietician services appropriately for the on-demand group.
We can almost presume that this study explored whether there
was an important signal to indicate a difference between the two
treatment groups in an exploratory randomized trial to further
explore nutritional and clinical endpoints in a larger randomized
controlled trial.
Previous studies have reported that nutritional counseling has
a positive influence on nutritional intake and clinical outcomes in
patients with HNSCC undergoing radiotherapy (2, 13, 14, 16) or
chemoradiotherapy (5, 6). Four studies showed that nutritional
intervention given by a dietician was more efficacious vs. no
counseling or general nutritional advice given by a nurse (2, 13,
14, 16). Two studies conducted in patients withHNSCC receiving
chemoradiotherapy have showed that weight loss decreased in
patients receiving nutritional intervention compared with no
intervention, while compliant patients lost less weight than non-
compliant patients (5, 6); it has also been suggested that nutrition
may improve long-term outcomes in colorectal cancer (20).
Nutritional counseling seemed more efficacious in patients
with more profound pre-treatment weight loss as these patients
lost less weight during their treatment compared with those
with no pre-treatment weight loss. This is contrary to previous
data showing that weight loss tends to persist during oncologic
treatment (6). The current study additionally showed that
overweight patients (BMI > 25 kg/m2) lost significantly more
weight due to more profound treatment-induced anorexia and
nausea. They still had clinically better muscle strength and
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TABLE 3 | Nutritional characteristics in patients according to baseline nutritional status and BMI.
Baseline nutritional status (PG-SGA) Baseline BMI, kg/m2
Characteristics Well-nourished Malnourished <25 ≥25
Number of patients, (%) 37 (64) 21 (36) 33 (57) 25 (43)
Weight loss, kg
6 mo pre-treatment 0.6 (−2 – 1) 6.3 (−6 – −1) 4.5 (0.1–7) 0.7 (0–4)
During treatment 5.5 (−11 – −5) 3.2 (−8–−1) 3.2 (1–5) 7.1 (5–9)
Differencea 5.1 (4.0, 6.2) 4.3 (2.7, 5.0) 3.5 (4.9, 2.1) 6.6 (8.2, 4.9)
p-value 0.476 0.021
Weight
Baseline 79.7 (68–89) 62.9 (53–76) 63.8 (56–68) 86.1 (82–93)
End 73.3 (62–81) 58.9 (53–70) 58.2 (53–66) 80.1 (74.86)
Differencea 68.0 (67.0, 69.1) 69.3 (67.9, 70.8) 69.0 (67.6, 70.4) 67.8 (66.1, 69.6)
p-value 0.158 0.368
BMI
Baseline 24.8 (23–28) 21.8 (18–25) 21.6 (19–23) 27.4 (26–29)
End 23.6 (21–26) 20.3 (19.23) 25.2 (24–26) 25.2 (24–26)
Differencea 22.6 (22.2, 22.9) 23.0 (22.6, 23.5) 23.0 (22.5, 23.4) 22.5 (21.9, 23.0)
p-value 0.144 0.269
FFM, kg
Baseline 61.3 (54–68) 47.2 (42–61) 51.1 (44–58) 66 (61–73)
End 58.6 (50–64) 47.4 (42–56) 47.0 (43–55) 64 (57–70)
Differencea 55.0 (53.9, 56.1) 55.7 (54.1, 57.2) 18.1 (17.6, 18.5) 18.6 (18.1, 19.1)
p-value 0.459 0.202
FFMI, kg/m2
Baseline 19.9 (19–22) 16.9 (14–20) 16.9 (16–19) 21.0 (20–23)
End 19.3 (17–20) 16.3 (16–18) 16.2 (16–18) 20.1 (19–22)
Differencea 18.3 (17.9, 18.6) 18.4 (17.9, 18.9) 18.1 (17.6, 18.5) 18.6 (18.0, 19.2)
p-value 0.249 0.202
HGS, kg
Baseline 39.3 (33–49) 28.0 (22–37) 31.3 (22–37) 42.3 (38–53)
End 38.0 (29–47) 27.3 (20–31) 28.0 (21–36) 40.7 (31–49)
Differencea 34.2 (32.8, 35.7) 32.6 (30.6, 34.6) 33.4 (31.7, 35.1) 32.0 (32.0, 35.9)
p-value 0.214 0.705
Data presented as median, IQ (interquartile) range. FFM, fat-free mass; FFMI, fat-free mass index; HGS, handgrip strength; PG-SGA, patient generated subjective global assessment;
OS, overall survival; DFS, disease-free survival.
aBaseline-adjusted mean difference (95% CI) at the end of treatment, where the baseline measurement is included as a continuous covariate (ANCOVA). Well-nourished patients are
compared to malnourished patients and patients with BMI < 25 kg/m2 are compared to patients with BMI ≥ 25 kg/m2.
muscle mass compared with patients with BMI ≤ 25 at the
end of treatment. This might explain the finding that treatment
induced weight loss was not associated with survival. Instead,
patients with either pre-treatment low HGS (<5th percentile)
or malnutrition (PG-SGA BC) had shorter DFS compared with
baseline normal HGS and good nutritional status.
Despite the fact that we did not find differences between
nutritional intervention groups, from a clinical point of view
it is important to refer that 69% of patients had difficulties in
achieving the planned nutritional treatment, which is in line with
the study by Capuano (53%) (6). The possible cause might be
the (chemo) radiotherapy induced adverse events, such as nausea
and anorexia, which were seenmore often in overweight patients.
As the majority of patients were obese, this had impact on study
results and might require more aggressive treatment of therapy
related adverse events in the future.
Malnutrition before treatment has been found in 60% of
patients with HNSCC according to PG-SGA, and at the end of
chemoradiotherapy it may increase up to 85% (2, 5). In line with
previous studies, we found malnutrition by PG-SGA to increase
from 31 to 86%. It is noteworthy that in PG-SGA, a weight-losing
patient is classified as malnourished even if the muscle mass loss
is substantial but still over 50th percentile. Our results indicate
that even though overweight patients lost significantly weight
they had at the end of chemoradiotherapy higher muscle mass
and HGS in comparison with low or normal BMI. Moreover,
patients with pre-treatment malnutrition had shorter survival
and DFS in comparison with well-nourished patients.
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Weight loss is a dominant feature among HNSCC patients.
Previous studies have reported a median weight loss before
chemoradiotherapy to be 4% and at the end of treatment to
reach 10% (6), which is in accordance with our results (7–8%).
Weight loss of more than 20% during chemoradiotherapy has
been associated with impaired survival (6, 17). In the current
study weight loss was not associated with impaired survival
due to that none of the patients lost weight more than 15%
and the median weight loss for all patients was <10%. Instead,
we found that overweight patients had higher risk of severe
weight loss, which has been observed previously among cancer
patients in general, as well as among Stage III-IV HNSCC
patients (35, 36). It seems that patients with higher pre-treatment
BMI had more nausea and anorexia, and thus greater weight
loss. This was also seen in the study by Prado et al. (37),
which showed that patients with sarcopenic obesity had more
chemotherapy related adverse events. Furthermore, overweight
patients may have more cytokines from adipose tissue delaying
gastric emptying and inducing nausea and anorexia (38). On
the other hand, energy requirements for overweight patients are
higher and harder to achieve during chemoradiotherapy due
to delayed gastric emptying, which may have led to impaired
nutrition through PEG. One explanation could be that patients
with lower BMI were after all heavy alcohol users, and thus
had less chemotherapy related adverse events such as nausea,
vomiting, and anorexia (39).
HGS has been shown to predict nutritional status and
survival in advanced stage cancer patients (40, 41). In our study,
malnourished patients had 29% lower HGS compared with well-
nourished ones, which is in line with a previous study (40). Our
results showed that patients with baseline HGS <5th percentile
hadmarkedly shorter survival and disease-free survival. Based on
these results, the association between HGS <5th percentile and
survival clearly needs to be validated in a larger cohort.
Energy and protein need should be at least 20% higher than
in current study. Based on the fact that weight stable patients
achieved 90% of the energy and protein intake while weight
losing patients achieved only 70%. Furthermore, a tube feed
with 2 kcal/ml of energy and 10 g/100ml of protein might be
more preferably than a product with 1.5 kcal/ml and 6 g/100ml,
which was used in the current study. The perceived anorexia
and fullness was seen especially in obese patients, which needs
more attention.
This exploratory prospective randomized trial has several
strengths: all patients received either radiotherapy or
chemoradiotherapy with curative intent for their primary
HNSCC. Nutritional status was assessed with validated methods,
performed by a single dietician. The number of patients was
lower than intended and the low sample size may have led to
Type II errors. Due to the small number of patients these results
should be handled with caution. However, the present series
comprised 74% of all eligible cases and was therefore considered
to be representative for the HNSCC patient population at our
institution. Yet, this study shows the difficulty of recruiting
an adequate sample size and highlights the importance of
conducting multi-center studies in the future. Furthermore,
these data can be used for organizing and targeting nutritional
therapies more appropriately and cost efficaciously by allocating
high-risk patients (weight-losing patients) at the start and the
format and duration of the therapy.
According to results of the current study we suggest that
nutritional counseling given by a dietician should be prior to
(chemo) radiotherapy and a follow-up visit at the third week
of (chemo) radiotherapy when treatment related side-effects
commonly appear. In addition, weight should be measured
weekly by a nurse and a dietician referral on-demand if weight
loss is seen. It is also clear that more effort should be devoted to
the prevention of muscle mass loss.
To our knowledge, this is the first study comparing
individualized intensive nutritional counseling with
individualized on-demand nutritional counseling given by
a dietician prior to and during oncologic treatment. On-
demand nutritional counseling seemed not inferior to intensive
counseling; this should be verified with larger number of patients.
Regardless of weight loss, there was no significant difference
in overall survival, completion of (chemo) radiotherapy or
functional outcomes between the study groups. Worse HGS and
malnutrition seemed to influence survival. The implementation
of nutritional counseling adapted to the clinical context
of each department seems mandatory. Furthermore, more
attention should be given to overweight patients submitted to
chemoradiotherapy. These results do emphasize the importance
of establishing multimodal nutrition teams to efficaciously
modulate individual nutritional aspects with the progession of
the clinical status of such patients.
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